Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8189989 | 0.76 | — | — | |
| SCHEMBL6978688 | 0.72 | HPGD (0.46) | HPGDKMT2ASMN1; SMN2HTR6KDM4E | |
| SCHEMBL31690364 | 0.71 | CRBN (0.39) | HPGDKMT2ASMN1; SMN2HTR6KDM4E | |
| SCHEMBL7490294 | 0.71 | HTR6 (0.36) | HPGDKMT2ASMN1; SMN2HTR6 | |
| SCHEMBL29132584 | 0.71 | HPGD (0.44) | HPGDKMT2ASMN1; SMN2HTR6KDM4E | |
| SCHEMBL6971798 | 0.69 | HTR6 (0.39) | HPGDKMT2ASMN1; SMN2HTR6 | |
| SCHEMBL6969158 | 0.69 | HTR6 (0.35) | HPGDKMT2ASMN1; SMN2HTR6 | |
| SCHEMBL24996420 | 0.68 | OPRM1 (0.33) | KMT2AOPRM1OPRL1 | |
| SCHEMBL18721134 | 0.68 | HTR6 (0.38) | HPGDKMT2ASMN1; SMN2HTR6KDM4E | |
| SCHEMBL17489068 | 0.67 | HTR6 (0.40) | HPGDKMT2ASMN1; SMN2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176445-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. | 2003-09-18 | — | — | US | disclosed |
| EP-1106615-B1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020042421-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | OKUMURA YOSHIYUKI (JP) | 2002-04-11 | — | — | US | disclosed |
| EP-1106615-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176445-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | HPGD 608/4885KMT2A 2262/4885SMN1; SMN2 4652/4885 |
| US-20020042421-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | HPGD 439/4885KMT2A 2208/4885SMN1; SMN2 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.